Business Of Biotech

Episodes

An Anthropological Lens On Leadership In Life Sciences With Bunka's Monika Sumra, Ph.D.

February 23, 2026

Applying anthropology to biotech: Dr. Monika Sumra explains how environment shapes leadership and performance, urging leaders to fix systems, not people.

Company Turnarounds And AI For Infectious Diseases With Seek Labs' Jared Bauer

February 16, 2026

Seek Labs' CEO Jared Bauer on company turnarounds and leveraging a full-stack AI platform for CRISPR therapeutics and diagnostics for infectious disease.

Bringing Curative Cell Therapies To Market with Kite Pharma's Cindy Perettie

February 9, 2026

Kite Pharma's Cindy Perettie discusses scaling curative CAR-T therapies, the necessity of partnerships, and advancing patient access beyond major centers.

BoB@JPM: Brian Hilberdink, Boehringer Ingelheim

February 2, 2026

Boehringer Ingelheim's US President Brian Hilberdink on leveraging private ownership for long-term innovation, commercial strategy, and obesity.

BoB@JPM: Ron Cooper, enGene

January 26, 2026

enGene CEO Ron Cooper on scaling biotechs, creative fundraising, strategic storytelling, and navigating from R&D to global commercialization.

BoB@JPM: Marc Salzberg, M.D., Airway Therapeutics

January 19, 2026

Airway Therapeutics' CEO Marc Salzberg on developing zelpoltide alpha for BPD, bridging academia-industry gaps, and navigating Phase 3 funding.

A Royalty Model For Value Creation With Zymeworks' Kenneth Galbraith

January 12, 2026

Zymeworks CEO Kenneth Galbraith discusses leveraging partnerships, long-term value, and a new royalty model for biotech success.

Life Science Connect Editors' Roundtable: Wrapping Up 2025 And Looking Ahead

January 5, 2026

Biotech editors recap 2025's funding winter and FDA shakeup, forecasting 2026's focus on AI, GLP-1s, RNA therapies, and China's rise.

Building Cell Therapy Companies With Kenai Therapeutics' Nick Manusos

December 29, 2025

Kenai Therapeutics CEO Nick Manusos on building a company around an iPSC therapy for Parkinson's, from spin-out to funding and clinical trials.

Modernizing Clinical Trial Operations With Merck's Jennifer Sheller

December 22, 2025

Merck's Jennifer Sheller discusses modernizing clinical trials through lean protocols, risk-based quality management, and a hybrid FSP model.

Transforming Chronic Kidney Disease With ProKidney's Bruce Culleton, M.D.

December 15, 2025

ProKidney CEO Bruce Culleton discusses disrupting chronic kidney disease (CKD) with autologous cell therapy to delay or eliminate dialysis.

Engineering B Cells With Immusoft's Sean Ainsworth

December 8, 2025

Immusoft CEO Sean Ainsworth on pioneering re-dosable B-cell therapies, his journey from the Navy to biotech, and lessons in fundraising & exits.

Building A Cancer Pipeline In A Molecule With Actuate Therapeutics' Dan Schmitt

December 1, 2025

Actuate Therapeutics CEO Dan Schmitt discusses developing a novel cancer drug, leading through a tough market, and efficient, lean operations.

Biotech Funding And IPO Temperature Check With Create Medicine's Allan Shaw

November 17, 2025

Biotech funding is recovering, fueled by M&A and a potential IPO revival. Success hinges on quality, strategic timing, and capital discipline.

Funding Tips And Moving From R&D To Commercial With Madrigal Pharmaceuticals' Mardi Dier

November 10, 2025

Madrigal CFO Marty Dier on launching the first MASH drug, transitioning from R&D to commercial, and navigating biotech capital markets.